Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1975 1
1980 1
1990 1
1991 2
1993 2
1998 2
2000 3
2001 1
2002 1
2004 1
2006 2
2007 4
2008 1
2009 1
2010 1
2011 2
2013 1
2014 4
2015 7
2016 7
2017 2
2018 3
2019 4
2020 6
2021 6
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Furie R, et al. Among authors: green y. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. N Engl J Med. 2020. PMID: 32937045 Clinical Trial.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA. Rovin BH, et al. Among authors: green y. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560137 Free article. Clinical Trial.
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH, Roth DA. Yu X, et al. Among authors: green y. Am J Kidney Dis. 2023 Mar;81(3):294-306.e1. doi: 10.1053/j.ajkd.2022.06.013. Epub 2022 Sep 2. Am J Kidney Dis. 2023. PMID: 36058429 Free article. Clinical Trial.
ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma.
Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acuña Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, Agarwal N, Liu X, Koh MY. Green YS, et al. Oncogene. 2022 Oct;41(42):4709-4723. doi: 10.1038/s41388-022-02460-1. Epub 2022 Sep 12. Oncogene. 2022. PMID: 36097192 Free PMC article.
Electrical Conductance of Charged Nanopores.
Green Y. Green Y. ACS Omega. 2022 Oct 6;7(41):36150-36156. doi: 10.1021/acsomega.2c02266. eCollection 2022 Oct 18. ACS Omega. 2022. PMID: 36278037 Free PMC article.
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
Anders HJ, Furie R, Malvar A, Zhao MH, Hiromura K, Weinmann-Menke J, Green Y, Jones-Leone A, Negrini D, Levy RA, Lightstone L, Tanaka Y, Rovin BH. Anders HJ, et al. Among authors: green y. Nephrol Dial Transplant. 2023 Nov 30;38(12):2733-2742. doi: 10.1093/ndt/gfad167. Nephrol Dial Transplant. 2023. PMID: 37463054 Free PMC article. Clinical Trial.
71 results